INTERIM REPORT JANUARY-JUNE 2007 • Group revenues from sales of goods and royalties amounted to 665.0 (686.2) MSEK during the period. • Growth within the Esthetics product area was 17 percent and revenues amounted to 537.1 (460.8) MSEK. • Operating income amounted to 318.2 (212.9) MSEK and the operating margin was 47.9 (34.7) percent. • Income after tax amounted to 284.0 (151.4) MSEK. • Earnings per share after full dilution were 2.86 (1.53) SEK. • RESTYLANE Perlane approved for sales in USA. In connection with approval, Q-Med received 29.1 MUSD from Medicis. Queries should be addressed to: Bengt Ågerup, President and CEO Tel: +46 (0)70-974 9025 Erika Kjellberg Eriksson, Vice President and CFO Tel: +46 (0)70-974 9020 Madelene Sandgren, Director Investor Relations and Corporate Communications Tel: +46 (0)70-974 9015
INTERIM REPORT JANUARY-JUNE 2007
| Source: Q-Med AB